Right-Sided clinical findings are worse prognostic factor in Multiple Sclerosis patients?

Asuman O. Varoglu, MD, Ece Balkuv, MD.

ABSTRACT

Objectives: To investigate the importance of the side of clinical findings in predicting the prognosis in multiple sclerosis (MS) patients.

Methods: In our study we enrolled 361 MS patients. This study as retrospective was performed. On neurological examinations, clinical findings were recorded as right, left and bilateral. We used the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Score (MSSS), Progression Index (PI) for neurological status.

Results: At the first attack, there were differences in the EDSS, PI and MSSS of right-sided findings between remission and attack periods (p=0.057, p=0.008, p=0.017 respectively). In the right-sided clinical findings, the value of PI and MSSS were higher than the others between in remission and attack periods (p=0.002, p=0.045 respectively). At last attack, we found statically differences in EDSS, MSSS values between remission and attack periods in only right-sided clinical findings (p=0.042, p=0.027 respectively). In the first presentation the PI value in bilateral clinical signs was lower (p=0.016).

Conclusion: Right-sided clinical findings were poor prognostic factors in all stages of MS, whereas bilateral findings were not poor prognostic factor in the early-stage MS.

Neurosciences 2020; Vol. 25 (2): 97-103
doi: 10.17712/nsj.2020.2.20190111

From the Department of Neurology, Medical Faculty, Istanbul Medeniyet University, Istanbul, Turkey.

Received 14th November 2019. Accepted 17th December 2019.

Address correspondence and reprint request to: Dr. Asuman Orhan Varoglu, Department of Neurology, Medical Faculty, Istanbul Medeniyet University, Istanbul, Turkey. E-mail: anorhan69@gmail.com

ORCID ID: https://orcid.org/0000-0002-4172-1299.

In the literature, there are many studies that investigate prognostic factors in patients with multiple sclerosis patients.1,2 Most of these studies are related to biomarkers.3,4 Many previous studies have described differences in brain modulation of immune function by right and left hemispheres.5,6,7 In animal studies, researchers showed that each hemicortex modulated lymphocyte reactivity in different ways.5 However, asymmetry of cell-mediated immunity in peripheral system has been demonstrated in some cancer cases.8-10 Using the tuberculin test, it was reported that cell-mediated immune hypersensitivity response in the left side was higher than right side in high-school students.11 The right neocortex suppressed functions of immune
system, whereas the left neocortex induced functions of immune system.\textsuperscript{12} Despite researchers reported asymmetry of cell-mediated immunity in peripheral system in various cancer types. We believe that our study is important in terms of leading the studies investigating the central asymmetry of cell-mediated immunity for other studies, including MS. Therefore, our aim in this study is to investigate the importance of right/left/bilateral-sided clinical findings for predicting the prognosis in MS.

**Methods.** This study was performed as retrospectively at Neurology Department, Istanbul Medeniyet University, Goztepe Research and Educational Hospital, Istanbul, Turkey. We recorded MS patients \( (n=361) \) between 2001 and 2016. In accordance with the 2010 McDonald criteria, we included aged 18-70 years with diagnosed of relapsing-remitting MS (RRMS), primary progressive MS (PPMS), or secondary progressive MS (SPMS) patients.\textsuperscript{13,14} We considered the patients under 14 years of age as pediatric onset and excluded from the study. The patients of MS were divided into relapse and remission periods. We considered the onset of symptoms as the duration of the disease. We taught that the first presentation sign is very important to evaluate prognosis of MS. The exclusion criteria were a history of neurodegenerative diseases or other neuroinflammatory diseases. The institutional ethics committee approved our study protocol. Ethics Approval Letter signed and stamped by Ethics Committee is presented.

Gender, age at onset of MS, family history of MS, MS type, MS drug treatment, education, existence of other disorders, duration of MS, and existence of MS lesions in supratentorial, infratentorial, and brainstem or spinal areas were recorded, in addition to the existence of CSF oligoclonal bands. We noted visual and sensorial evoked potentials from hospital charts. On neurological examinations, findings were classified as right unilateral, left unilateral, or bilateral in both attack and remission periods.

To evaluate disability, the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Score (MSSS), Progression Index (PI) were used\textsuperscript{14,16} in both attack and remission periods. PI used (PI=EDSS/time from onset in years) in order to evaluate disability for the disease duration. As it is generally considered that very slow PI (0.20 or less) has at least approximately as good prognostic value.

The Extended Disability Situation Scale (EDSS) was also used and if the EDSS score is 0-3.5, it is considered mild and if the EDSS score is 4-9.5 it is considered moderate / severe MS. To determine MSSS (Multiple Sclerosis Scale Score) can be use a program from [http://www-gene.cimr.cam.ac.uk/MSgenetics/GAMES/MSSS](http://www-gene.cimr.cam.ac.uk/MSgenetics/GAMES/MSSS). The score is from 0 to 10 - low is good, high is bad. At all visits, right optic neuritis, left optic neuritis, right pyramidal sign, left pyramidal sign, right sensory sign, left sensory sign, right cerebellar sign, left cerebellar sign, intestinal bladder sign, and brainstem sign were checked. Bilateral pyramidal signs, bilateral sensory signs, bilateral cerebellar signs, bilateral optic neuritis, intestinal bladder signs and brainstem signs were accepted as bilateral clinical findings. The other clinical findings were accepted as right or left sided clinical findings. We tried to control patients with at least 6 months intervals. There were also patients who came more frequently or later than this range. We used the neurological disability of the first and last lateralized clinical findings in order to obtain a more accurate result when performing the statistical analysis of the patients.

**Statistical analysis.** We used the Number Cruncher Statistical System 2007 (Kaysville, Utah, USA) program. We applied that statistical methods (mean, standard deviation, median, frequency, odds, minimum, maximum) for descriptive analysis. For comparing 2 groups of parameters we used Mann–Whitney U test in the quantitative data which does not conform to a normal distribution. We used the Kruskal–Wallis test for comparisons of 3 groups not having normal distribution. To compare for intra-group of parameters not having normal distribution we used the Wilcoxon signed-ranks test. We used Spearman’s correlation analysis to assessment interparameter relationships. We reported data as mean ± standard deviation. if \( p<0.05 \) was considered significant.

**Results.** In our study, 251 (69.5\%) participants were females, and 110 (30.5\%) were males. The patients were aged 19–69 years, the mean age was 40.65±9.97 years. Table 1 shows the patients’ demographic features. The duration of the disease ranged from 1 to 43 years, mean 10.98±7.94 years. Age of onset of the disease ranged from 14 to 58, mean 30.42±8.70 years. Regarding family medical history, MS was found in first-degree relatives in 5.5\% (n=20) of cases and present in second-degree relatives in 1.4\% (n=5) of cases. There was no family history of MS in 93.1\% (n=336) of cases.

**Disclosure.** Authors have no conflict of interests, and the work was not supported or funded by any drug company.
Additional diseases were present in 64.7% (n=234) of cases. Depression was observed in 13.6% (n=49) of MS patients. The average follow-up was 4.97±3.80 months.

The EDDS ranged from 0 to 8.5, with a mean of 2.34±2.00. The PI measurements ranged from 0 to 6.5, with an average of 0.52±0.62. The MSSS ranged from 0 to 97, with a mean of 44.50±26.66.

In the attack periods, right optic neuritis was observed in 1.5% (n=27) of cases, and left optic neuritis was detected in 2.0% (n=38) of subjects. The right pyramidal signs were present in 2.5% (n=49) of cases, and the left pyramidal signs were present in 4.4% (n=82) of cases. The right sensory signs were detected in 4.8% (n=90) of cases, and the left sensory signs were detected in 0.8% (n=14) of cases. The right cerebellar signs, left cerebellar signs, intestinal bladder signs, and brainstem signs were detected in 0.8% (n=14), 0.9% (n=16), 0.2% (n=4), and 1.8% (n=33) of cases, respectively.

In the remission periods, right optic neuritis was observed in 13.9% (n=258) of cases, and left optic neuritis was observed in 14.4% (n=267) of cases. The right pyramidal signs were observed in 27.6% (n=512) of cases, and the left pyramidal signs were detected in 13.7% (n=254) of cases. The right sensory signs, left sensory signs, right cerebellar signs, left cerebellar signs, intestinal bladder signs, and brainstem signs were detected in 13.6% (n=252), 12.1% (n=225), 12.4% (n=231), 38.4% (n=714), and 20.9% (n=388) of cases, respectively.

Gender and family history were not prognostic indicators (p>0.05). According to the EDSS, older age was associated with a worse prognosis (p<0.01), although this relationship was not confirmed by the MSSS or PI. In evaluations of the EDSS, PI, and MSSS during the first attack periods in MS patients, only the PI was lower in patients with bilateral clinical signs than those with right- or left-sided clinical signs (p=0.016), as shown in Table 2.

At the time of the first attack, the difference in the EDSS between remission and attack periods was not statistically significant among patients with right/left/bilateral clinical findings (p>0.05). It was the only remarkable reduced measurement at the right-sided clinical signs (p=0.057). When the EDSS of patients was compared according to the side of clinical signs, there was no difference among patients with right unilateral, left unilateral, or bilateral clinical findings (p>0.05). During the last attack, we found statistically significant difference in the EDSS in patients with only right-sided clinical signs between remission and attack periods (p=0.042) (Table 3).

At the time of the first attack, PI values were lower in those with bilateral clinical signs than other sided clinical sign values during the attack period (p=0.001). The difference in PI values between remission and attack periods was statistically significant in patients with right-sided clinical signs (p=0.008) and bilateral-sided clinical signs (p=0.036). The differences between the remission and attack periods measurements are statistically significant compared to the groups. The difference in PI values between remission and attack periods in patients with right-sided clinical signs was higher compared to the difference in PI values between remission and attack periods in patients with left and bilateral sided clinical signs. (p=0.002). At the last attack, for PI values we found no significant difference between remission and attack periods (Table 3).

During the first attack, MSSS values of patients with left-sided clinical findings were higher than patients with other sided clinical findings in the remission periods (p=0.007). The difference in MSSS values

Table 1 - The demographic features of multiple sclerosis patients.

| Age (year) | n (%) |
|-----------|-------|
| Min-Max (Median) | 19-69 (40) |
| m±SD | 40.70±10.05 |
| Gender n (%) | |
| Female | 251 (69.5) |
| Male | 110 (30.5) |
| Duration of illness(year) | |
| Min-Max (Median) | 1-43 (8) |
| m±SD | 10.98±7.94 |
| Age of onset of illness(year) | |
| Min-Max (Median) | 14-58 (29) |
| m±SD | 30.42±8.70 |
| Educationstatus n (%) | |
| Noliterate | 14 (3.8) |
| Primaryschool | 170 (47.1) |
| High school | 95 (26.4) |
| License | 74 (20.5) |
| Graduate | 8 (2.2) |
| Familyhistory n (%) | |
| MS absent | 336 (93.1) |
| First degreerelative | 20 (5.5) |
| Second degreerelative | 5 (1.4) |
between remission and attack periods was statistically significant in those with right-sided clinical findings ($p=0.017$). The difference in PI values between remission and attack periods in patients with right-sided clinical signs was higher compared to the difference in PI values between remission and attack periods in patients with left and bilateral sided clinical signs ($p=0.045$). At the time of the last attack, MSSS values of patients with only right-sided clinical findings there was a significant difference between in remission and attack periods ($p=0.027$), as shown in Table 3.

In patients with infratentorial lesions, EDSS values were higher than those of patients without infratentorial lesions in both remission and attack periods ($p=0.029$, $p=0.016$, respectively). Not detected significant difference in EDSS values of infratentorial lesion of patients between remission and attack periods ($p=0.035$).

In patients with spinal lesions, EDSS and MSSS values were higher in those without spinal lesions in both remission ($p=0.022$; $p=0.027$, respectively), attack periods ($p=0.002$; $p=0.008$ respectively). There was no significant difference for PI values in patients with spinal lesions between remission and attack periods ($p=0.009$).

In patients with brainstem lesions, EDSS and MSSS values were higher in patients with brainstem lesions than in those than without brainstem lesions in both remission ($p=0.006$; $p=0.016$, respectively), attack periods ($p=0.012$; $p=0.030$, respectively). The PI values were also high in the remission period in patients with brainstem lesions ($p=0.012$).

In patients with supratentorial lesion, we found no statistically significant difference for the EDSS, PI, or MSSS values ($p=0.05$). In terms of lateralized clinical findings, we found no difference in the EDSS, PI, or MSSS values ($p>0.05$) of patients with RRMS, PPMS, SPMS.

In MS patients with additional diseases and disorders, such as collagenous tissue disease, and depression, we found no difference in the EDSS, PI, or MSSS values ($p>0.05$) compared with patients with MS without these diseases.

**Discussion.** Asymmetrical modulation of the immune system, peripheral system, and central nervous systems has been reported.\textsuperscript{17} In an animal study, Shen et al\textsuperscript{18} reported that interleukin-6 played an important function in asymmetrical brain immunomodulation in brain. Previous studies reported peripheral asymmetry of cell-mediated immunity in various diseases.\textsuperscript{11,18} Clinical research studies also reported differences in immunomodulatory effects of right and left hemispheres, in addition to immune asymmetry mediated by peripheral cells in some diseases.\textsuperscript{18,19} In the present study, neurological disability as assessed by the EDSS, PI, and MSSS was worse in patients with right-sided clinical findings at the time of the first attack as compared with that of patients with other sided clinical findings. In addition, right-sided clinical findings were worse for EDSS and MSSS at the last attack as compared with that of patients with other sided clinical findings. In light of these data, we conclude that right-sided clinical findings were worse as compared with those with left- and bilateral-sided clinical findings in earlier and later stages of MS.

As can be seen from Table 3, in the first attack, neurological disabilities in patients with right lateralized findings were poor for EDSS, PI and MSSS ($p<0.05$); in the last attack, neurological disabilities in patients with right lateralized findings were poor for EDSS and MSSS ($p<0.05$). Therefore, we can say that right lateralized findings were poor prognostic factor. Although, neurological disabilities in patients with bilateral lateralized findings were not poor for EDSS, PI

---

### Table 2 - Evaluating of EDSS, PI and MSSS only at the first attacks in MS patients.

|                  | EDSS     | PI        | MSSS     |
|------------------|----------|-----------|----------|
|                  | n=78     | n=11      | n=6      | n=53     |
| Min-Max(Median)  | 1-6.5 (2)| 0.2-3.3 (1)| 18-96 (67)|          |
| Mean±SD          | 2.59±1.43| 1.33±1.07 | 56.64±26.45|          |

In patients with additional diseases and disorders, such as collagenous tissue disease, and depression, we found no difference in the EDSS, PI, or MSSS values ($p>0.05$) compared with patients with MS without these diseases.
Right-Sided clinical findings are bad ...

Table 3 - Evaluation of EDSS, PI and MSSS Value of Side of Clinical Findings in the Remission and Attack Periods at the first and last attacks.

|                      | The First attack side of clinical findings | The Last attack side of clinical findings |
|----------------------|------------------------------------------|-----------------------------------------|
|                      | Right (n=36)                              | Left (n=39)                             | Bilateral (n=183) | *P-value | Right (n=8)    | Left (n=7)   | Bilateral (n=259) | *P-value |
| **EDSS**             |                                          |                                         |                  |          |                |              |                     |          |
| Remission            | Min-Max (Median)                          | 0-4.5 (1)                              | 0-7 (1.5)        | 0-8 (1.5) | 0.123          | 1-3.5 (2)    | 1-6.5 (2)          | 0.139    |
|                      | Mean±SD                                  | 1.47±1.22                              | 2.24±1.75        | 2.29±2.04 | 2.14±1.03      | 3.29±2.27    | 2.12±1.88          |          |
| Attack               | Min-Max (Median)                          | 0-4 (2)                                | 0-7 (2)          | 0-8.5 (2) | 0.860          | 1-5.5 (2.5)  | 1-5 (3)            | 0.191    |
|                      | Mean±SD                                  | 1.93±0.91                              | 2.40±1.80        | 2.46±2.08 | 2.88±1.60      | 2.93±1.48    | 2.34±1.92          |          |
| b p-value            |                                          | 0.057                                  | 0.660            | 0.224     | 0.042*         | 1.000        | 0.058              |          |
| Difference (Attack-Remission) | Min-Max (Median) | -2.5-3 (0.5) | -5-7 (0) | -6-5-6 (0) | 0.630 | 0-2 (1) | -5-2 (0) | -6-5-7 (0) | 0.331 |
|                      | Mean±SD                                  | 0.46±1.35                              | 0.15±2.19        | 0.18±2.40 | 1.00±0.87      | -0.36±2.39   | 0.22±2.24          |          |
| **PI**               |                                          |                                        |                  |          |                |              |                     |          |
| Remission            | Min-Max (Median)                          | 0-2 (0.3)                              | 0-3.5 (1)        | 0-6-5 (0.5) | 0.126          | 0-3-3 (1)    | 0-3.65 (0.7)       | 0-5-5.5 (0.5) | 0.078 |
|                      | Mean±SD                                  | 0.66±0.70                              | 0.93±0.79        | 0.75±0.89 | 1.29±0.86      | 1.47±2.23    | 0.75±0.78          |          |
| Attack               | Min-Max (Median)                          | 0-3 (1)                                | 0-4 (0.6)        | 0-6-5 (0.3) | 0.001**       | 0-3-5 (0.8) | 0.2-1.5 (0.4)      | 0.6-5 (0.4) | 0.350 |
|                      | Mean±SD                                  | 1.16±0.89                              | 1.06±1.02        | 0.62±0.79 | 1.30±1.56      | 0.63±0.47    | 0.79±0.90          |          |
| b p-value            |                                          | 0.008**                                | 0.712            | 0.036*    | 1.000          | 0.068        | 0.804              |          |
| Difference (Attack-Remission) | Min-Max (Median) | -1.8-2.5 (0.5) | -3.1-2.4 (0) | -5.5-5 (0) | 0.002** | -1.6-2 (0.1) | -5-0 (-0.1) | -5-5-5 (0) | 0.385 |
|                      | Mean±SD                                  | 0.50±1.04                              | 0.11±1.21        | -0.13±1.04 | 0.02±1.17      | -0.85±1.85   | 0.04±1.08          |          |
| **MSSS**             |                                          |                                        |                  |          |                |              |                     |          |
| Remission            | Min-Max (Median)                          | 0.81 (32)                              | 10-93 (50)       | 0-94 (36) | 0.007**        | 30-88 (50)   | 12.92 (50)         | 0-94 (36.5) | 0.432 |
|                      | Mean±SD                                  | 35.29±21.69                            | 53.90±26.1       | 41.83±26.07 | 57.00±25.85   | 48.33±32.95  | 43.29±25.77        |          |
| Attack               | Min-Max (Median)                          | 8-90 (50)                              | 10-93 (42)       | 0-93 (36) | 0.066          | 30-93 (70.5) | 12-88 (50)         | 0-93 (37) | 0.071 |
|                      | Mean±SD                                  | 50.69±24.53                            | 52.24±25.92      | 43.13±26.93 | 68.13±22.00   | 49.86±30.73  | 45.92±26.83        |          |
| b p-value            |                                          | 0.017*                                 | 0.581            | 0.450     | 0.027*         | 0.593        | 0.153              |          |
| Difference (Attack-Remission) | Min-Max (Median) | -45-73 (19) | -61-83 (-2) | -91-81 (0) | 0.045* | -50 (9) | -42-25 (0) | -91-83 (0) | 0.290 |
|                      | Mean±SD                                  | 15.40±33.13                            | -0.84±34.66      | 1.55±31.80 | 16.57±17.33   | -3.33±21.59  | 3.20±33.48         |          |

a Kruskall Wallis Test, b WilcoxonSignedRanks Test, *p<0.05, **p<0.01, EDSS - Expanded Disability Status Scale, PI - Progression Index, MSSS - Multiple Sclerosis Severity Score

and MSSS in the first and last attacks (p>0.05), except for PI in the first attack (p=0.036). Therefore, we can say that bilateral findings were not poor prognostic factor. Also, the poor do not mean to be good. We can not say that bilateral findings are a good prognostic factor.

The right lateralized findings were poorer prognostic signs in both the first attack and last attack than the other lateralized signs, however, left and bilateral lateralized signs do not have this feature statistically. The left common carotid artery intima-media thickness (CCA-IMT) is greater than right. Non-lacunar cerebro-vascular ischemic events were also reported to be more common in the left hemisphere than right hemisphere. The patho-physiological mechanism of strokes in the more often left hemisphere, still unclear the left CCA-IMT was higher than the right. In a previous study, Algra et al indicated that the risk of sudden death is increased in the left-sided brain infarctions. Therefore, the left hemisphere appears to be more sensitive than the right hemisphere to hemodynamic stress and endothelial dysfunction. In the present study, we demonstrated that neurological disabilities were worse in those with clinical findings affecting the left hemisphere as compared with those of patients with findings affecting the right hemisphere in early and later stages of MS.

Previous research demonstrated that the production of cytokines differs between hemispheres, and the
levels of interleukin-1 and interleukin-6 of the right neocortex were higher than left neocortex of animals. In central nervous system infections, trauma, ischemia, and convulsions, the production of these 2 cytokines increased. After partial resection of the left fronto-parietal cerebral neocortex, immunoglobulin production, natural killer cell activity, T-cell activity mitogen-induced T-cell responses, and synthesis of modulating factors are reduced. Similarly of this report, Bardos et al reported that natural killer cells were controlled by the left-brain neocortex. Therefore, we thought that the right hemisphere may have a more important function than the left hemisphere in suppression of immune function disorders. As a result, the left hemisphere maybe more vulnerable to CNS immune disorders.

In the current study, the presence of bilateral-sided clinical findings was not an indicator of a poor prognosis in patients with early-stage MS. Thus, we concluded that compensatory mechanisms may be more effective in the presence of bilateral involvement than unilateral involvement. Consistent with previous studies, we found the prognosis of patients with infratentorial, spinal, and brainstem lesions was poorer than that of patients without these lesions. The presence of epilepsy, collagenous tissue disease, and depression had adverse effects against MS, in accordance with findings of recent studies.

The present study has a number of limitations due to its retrospective design. There were some published clinical reports investigating the presence of peripheral asymmetry of cell-mediated immunity. In the literature, there is not any clinical report investigating central immune asymmetry in terms of clinical findings. The study also benefits from a large number of patients. The findings can shed light on new studies regarding the differences of immunity between both hemispheres. Despite we did not evaluate any relationship between dominant and non-dominant sides and the side affected we believe that our study is important in terms of leading the studies investigating the central asymmetry of cell-mediated immunity for other studies, including MS.

In conclusion, we suggest that the prevalence of bilateral-sided clinical signs are not a poor prognostic factor in the early stage of MS. The presence of infratentorial, spinal, and brainstem lesions served as prognostic indicators of the extent of neurological disability. Neurological disabilities associated with clinical findings in the left hemisphere were worse in early and later stages of MS. Early observation of the presence of right-sided clinical signs can aid clinicians in selecting patients for early immunomodulatory or immunosuppressant treatments.

References

1. Al-Abdullah MS, Siddiqui AF. Demographic and disease characteristics of multiple sclerosis in the Southwest Region of Saudi Arabia. *Neurosciences* (Riyadh) 2018; 23: 320-325.
2. Fragomeni MO, Bichuetti DB, Oliveira EML. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders. *Mult Scler Relat Disord* 2018; 25: 138-142.
3. Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D, et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? *J Neurol* 2018; 265: 424-430.
4. Novakova L, Axelson M, Malmström C, Imberg H, Elias O, Zetterberg H, et al. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. *PLoS One* 2018; 13: e0194828.
5. Neveu PJ, Betancur C, Barneoud P, Vitiello S, Le Moal M. Functional brain asymmetry and lymphocyte proliferation in female mice: effects of right and left cortical ablation. *Brain Res* 1991; 31: 125-128.
6. Gontova IA, Abramov VV, Kozlov VA. Asymmetry of delayed type hypersensitivity reaction in mice. *Bull Exp Biol Med* 2003; 135: 67-69.
7. Gontova IA, Abramov VV, Kozlov VA. The role of asymmetry of nervous and immune systems in the formation of cellular immunity of (CB×C57Bl/6) F1 mice. *Neuroimmunomodulation* 2004; 11: 385-391.
8. Dane S, Borekci B, Kadanali S. Right-sided lateralisation of ovarian cancer and right bias asymmetry for involved pelvic lymphnodes by ovarian cancer cells. *Laterality* 2008; 13: 393-402.
9. Yoruk O, Karasan M, Timur H, Erdem T, Dane S, Tan U. Lateralizations of head-neck cancers are not associated with peripheral asymmetry of cell-mediated immunity. *Int J Neurosci* 2009; 119: 815-820.
10. Kramer MA, Albrecht S, Miller RA. Handedness and the laterality of breast cancer in women. *Nurs Res* 1985; 34: 333-337.
11. Dane S, Erdem T, Gümüştekin K. Cell-mediated immune hypersensitivity is stronger in the left side of the body than the right in healthy young subjects. *Percept Mot Skills* 2001; 93: 329-332.
12. Fu QL, Shen YQ, Gao MX, Dong J, Neveu PJ, Li KS. Brain interleukin asymmetries and paw preference in mice. *Neuroscience* 2005; 116: 639-647.
13. Nedeljkovic U, Lackovic J, Tepavcevic DK, Basuroski ID, Mesaros S, Pekmezovic T, et al. Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial. *Arch Med Sci* 2016; 12: 380-389.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). *Neurology* 1983; 33: 1444-1452.
15. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. *Neurology* 2005; 64: 1144-1151.
16. Cendrowski WS. Progression index and disability status in multiple sclerosis: a resurvey of 207 patients in central Poland. *Schweiz Arch Neurol Psychiat* 1986; 137: 5-13.
17. Gerendai I, HalászB. Neuroendocrine asymmetry. *Front Neuroendocrinol* 1997; 18: 354-381.
18. Shen YQ, Hébert G, Moze E, Li KS, Neveu PJ. Asymmetrical distribution of brain interleukin-6 depends on lateralization in mice. *Neuroimmunomodulation* 2005; 12: 189-194.
19. Algra A, Gates PC, Fox AJ, Hachinski V, Barnett HJ. North American Symptomatic Carotid Endarterectomy Trial Group. Side of brain infarction and long-term risk of sudden death in patients with symptomatic carotid disease. *Stroke* 2003; 34: 2871-2875.
20. Denarié N, Gariepy J, Chironi G, Massonneau M, Laskri F, Salomon J, et al. Distribution of ultrasonographically-assessed dimensions of common carotid arteries in healthy adults of both sexes. *Atherosclerosis* 2000; 148: 297-302.
21. Rodríguez Hernández SA, Kroon AA, vanBoxtel MP, Mess WH, Lodder J, Jolles J, et al. Is there a side predilection for cerebrovascular disease? *Hypertension* 2003; 42: 56-60.
22. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. *Physiol Rev* 1999; 79: 1-71.
23. Renoux G, BizièRE K, Renoux M, Guillaumin JM, Degenne DA. Balanced brain asymmetry modulates T cell-mediated events. *J Neuroimmunol* 1983; 5: 227-238.
24. Bardos P, Degenne D, Lebranchu Y, BizièRE K, Renoux G. Neocortical lateralization of NK activity in mice. *Scand J Immunol* 1981; 13: 609-611.
25. Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. *Mult Scler* 2018; 24: 301-312.
26. Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. *Neurology* 2016; 87: 1368-1374.
27. Jetté N, Amoozegar F, Patten SB. Depression in epilepsy, migraine, and multiple sclerosis: Epidemiology and how to screen for it. *Neurol Clin Pract* 2017; 7: 118-127.
28. Pauwels I, Cosemans L, Boonen S, Dubois B, Goris A. Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease. *Mult Scler* 2013; 19: 1132-1136.

---

**Statistics**

Excerpts from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals updated November 2003. Available from [www.icmje.org](http://www.icmje.org)

Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as the use of *P* values, which fails to convey important information about effect size. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the computer software used.